• Accelerator

P4ML

  • Health
  • Cohort 3 2020
  • Alumni
  • Accelerator

P4ML

  • Health
  • Cohort 3 2020
  • Alumni

What They Do

P4 Medical and Clinical Innovation Ltd. (P4ML) is Ireland’s first ever precision medicine company, specialising in genetic sequencing and mass spectrometry workflows. P4ML’s world-class analytical capabilities will change the way care is delivered to patients with the rarest of diseases by delivering comprehensive and integrated diagnostics via MultiOMICS
We aim to revolutionise the way in which society and policy makers think about health by understanding in detail the individuals’ genetic profile and adapting targeted treatments to address the patients’ needs. Our Vision is one of collective health intelligence through the building of a global medical community, where data and knowledge is shared. P4ML honours people’s needs for data security and privacy protection, their hopes for ground breaking medical advances, and their desire to be in control of how their data is used. Our mission supports connectivity of clinicians and data sharing in order to inform, empower and transform health and wellness. P4ML works directly with clinicians, thus ensuring consent, data protection regulations and ethical requirements are complied with.

 

from Ireland

About the founder

PJ Moloney (CEO/Founder)  has excelled as a globally recognized subject matter expert in the areas of drug discovery and development. A proven entrepreneur, PJ is a member of the Forbes Business Council and also a mentor for life sciences companies at AREA2071 in the UAE and the P4 Precision Medicine Accelerator in London. Notable achievements throughout his career both nationally and internationally include been awarded the following. (Life Sciences – Top 50 CEO’s; Young Leader of the Year – Irish Laboratory Awards, Outstanding Small Business in Ireland). PJ has won public and private tenders for fields of science in drugs of abuse testing; food adulteration; biopharmaceutical characterization and immunosuppressant.

 

Initiative by

Supported by